
AstraZeneca's liver cancer trial shows 30% progression-free survival improvement with new STRIDE regimen.
AstraZeneca's Phase 3 EMERALD-3 trial demonstrated that the STRIDE regimen, combining immunotherapy drugs Imfinzi and Imjudo with lenvatinib and TACE, significantly improved progression-free survival by 30% compared to TACE alone in patients with unr...


